{"id":"avb-114","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":{"chemblId":"CHEMBL3644359","moleculeType":"Protein","molecularWeight":"1058.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AVB-114 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine. This leads to a decrease in blood glucose levels. By targeting SGLT2, AVB-114 aims to improve glycemic control in patients with type 2 diabetes.","oneSentence":"AVB-114 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:03.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04847739","phase":"PHASE2","title":"Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avobis Bio, LLC","startDate":"2021-09-13","conditions":"Perianal Fistula, Crohn's Disease","enrollment":60},{"nctId":"NCT06509828","phase":"","title":"Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection","status":"AVAILABLE","sponsor":"Avobis Bio, LLC","startDate":"","conditions":"Perianal Fistula Due to Crohn's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AVB-114","genericName":"AVB-114","companyName":"Avobis Bio, LLC","companyId":"avobis-bio-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AVB-114 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}